Phase 3 Clinical Trials With Primary Completion Dates in April 2023
This is a list of Phase 3 trials with primary completion dates in April 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ACHV||Achieve Life Sciences, Inc.||2023-04-01||Phase 3||NCT05206370||A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers|
|BTTX||Better Therapeutics, Inc.||2023-04-01||Phase 3||NCT05094401||Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes|
|BVNRY||Bavarian Nordic A/S||2023-04-01||Phase 3||NCT05329220||ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2|
|CASBF||CanSino Biologics Inc.||2023-04-01||Phase 3||NCT05517642||IH Convidecia as Second Booster Dose Against Breakthrough Infections|
|EYPT||EyePoint Pharmaceuticals, Inc.||2023-04-01||Phase 3||NCT05070728||Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)|
|IONS||Ionis Pharmaceuticals, Inc.||2023-04-01||Phase 3||NCT04136184||NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy|
|KOD||Kodiak Sciences Inc.||2023-04-01||Phase 3||NCT04603937||A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)|
|KRON||Kronos Bio, Inc.||2023-04-01||Phase 3||NCT05020665||A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia|
|LIAN||LianBio||2023-04-01||Phase 3||NCT05174416||A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM|
|MNKD||MannKind Corporation||2023-04-01||Phase 3||NCT04974528||Afrezza® INHALE-1 Study in Pediatrics|
|RARE||Ultragenyx Pharmaceutical Inc.||2023-04-01||Phase 3||NCT05139316||A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)|